HYPERPOLARISED HELIUM HE-3
COPD
University of Massachusetts, WorcesterSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
22 Active assets in the COPD cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Liraglutide Claus Bogh Juhl | Phase 4 | BB |
Roflumilast Prince of Songkla University | Phase 3 | BB |
Ciprofloxacin Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Phase 4 | BB |
.ALPHA.-1 PROTEASE INHIBITOR Takeda | Phase 4 | BB |
Tazobactam Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Phase 4 | BB |
View all 50 →
Same molecule, other indications
HYPERPOLARISED HELIUM HE-3 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →